Manage the complexity of end-to-end continuous processes by creating automated feedback loops. Integrating real-time analytics, like an online HPLC, with mechanistic models allows for the dynamic, on-the-fly adjustment of downstream unit operations based on live upstream performance, optimizing the entire system.

Don't start by pitching a full-scale, real-time digital twin. Instead, use historical data to build an offline model and demonstrate concrete business value, such as a potential yield increase. This proven ROI makes it much easier to get executive backup and funding for the more expensive live implementation.

Before building a complex digital twin, Takeda analyzed historical manufacturing data. A simple end-to-end model identified that changing set points for six parameters—within existing validated ranges—could boost yield by 35%, demonstrating massive value in data that companies already possess.

The future of bioprocess development involves using AI on high-throughput data for predictive modeling. This, combined with in silico simulations (digital twins), will allow scientists to understand underlying biological mechanisms, not just identify optimal conditions, dramatically accelerating optimization.

Instead of aiming for a massive, all-encompassing digital twin, identify a critical business bottleneck first. Build a focused, end-to-end offline model to prove its value. Only after demonstrating a clear return on investment should you scale it into a real-time, fully integrated system. This 'moonshot before Mars' approach minimizes risk and builds momentum.

The term 'digital twin' is often misused. It represents the final stage of a three-step evolution: 1) a Digital Model (offline simulation), 2) a Digital Shadow (receives real-time data), and 3) a Digital Twin. The critical distinction of a true twin is its ability to feed recommendations back to influence the physical process, creating a closed loop.

Many assume vast amounts of data are necessary for a digital twin. In reality, process validation data combined with a handful of manufacturing trends is often sufficient. The focus should be on data quality and its relevance to a specific business decision, not sheer quantity. This approach makes powerful modeling accessible much earlier.

Instead of immediately building complex models for a single problematic unit operation, start with simple linear models that connect the entire process. This holistic view reveals which parameters truly impact the final drug substance, allowing you to focus resources on building complex models only where they are most critical.

The regulatory pathway for deploying models in manufacturing is not an unknown frontier. It involves a credibility assessment for the model itself, following standards like ASME VNP 40, and established GAMP procedures for validating the data interfaces. This treats the model and its integration as distinct, manageable components with clear guidelines.